Five Prime Announces Closing of Upsized Public Offering of Common Stock
November 17 2020 - 4:00PM
Business Wire
Underwriters Fully Exercise Option to Purchase
Additional Shares
Five Prime Therapeutics, Inc. (Nasdaq: FPRX) announced today the
closing of its upsized underwritten public offering of 8,280,000
shares of its common stock, which includes 1,080,000 shares sold
upon the underwriters’ full exercise of their option to purchase
additional shares, resulting in aggregate gross proceeds of
approximately $173.9 million, before deducting underwriting
discounts and commissions and estimated offering expenses payable
by Five Prime.
Cowen and SVB Leerink acted as joint book-running managers for
the offering. Wedbush PacGrow acted as co-manager for the
offering.
The shares of common stock were offering pursuant to a “shelf”
registration statement previously filed with and declared effective
by the Securities and Exchange Commission (SEC). The offering is
being made only by means of a prospectus supplement and
accompanying prospectus, copies of which may be obtained from Cowen
and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, Attention: Prospectus
Department, by telephone at (833) 297-2926 or by email at
PostSaleManualRequests@broadridge.com, or SVB Leerink LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA, 02110, by telephone at (800) 808-7525, ext. 6132 or by
e-mail at syndicate@svbleerink.com.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201117006258/en/
Martin Forrest VP, Investor Relations & Corporate
Communications Five Prime Therapeutics, Inc. 415-365-5625
martin.forrest@fiveprime.com
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Apr 2024 to May 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From May 2023 to May 2024